Literature DB >> 10168037

Cost utility in second-line metastatic breast cancer.

G Berdeaux, P Hurteloup.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 10168037     DOI： 10.2165/00019053-199711050-00012

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  7 in total

Review 1.  Vinorelbine: an overview.

Authors:  S A Johnson; P Harper; G N Hortobagyi; P Pouillart
Journal:  Cancer Treat Rev       Date:  1996-03       Impact factor: 12.111

2.  A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.

Authors:  R Launois; J Reboul-Marty; B Henry; J Bonneterre
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

3.  [Late phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section)].

Authors:  T Tominaga; Y Nomura; I Adachi; H Aoyama; K Nagao; S Mitsuyama; Y Nakamura; M Ogita; M Sano; S Takashima
Journal:  Gan To Kagaku Ryoho       Date:  1994-05

Review 4.  Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.

Authors:  K L Goa; D Faulds
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

5.  Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.

Authors:  G Gasparini; O Caffo; S Barni; L Frontini; A Testolin; R B Guglielmi; G Ambrosini
Journal:  J Clin Oncol       Date:  1994-10       Impact factor: 44.544

6.  Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer.

Authors:  M Degardin; J Bonneterre; B Hecquet; J M Pion; A Adenis; D Horner; A Demaille
Journal:  Ann Oncol       Date:  1994-05       Impact factor: 32.976

7.  Vinorelbine as single agent in pretreated patients with advanced breast cancer.

Authors:  S Barni; A Ardizzoia; G Bernardo; S Villa; M R Strada; M Cazzaniga; C Archili; L Frontini
Journal:  Tumori       Date:  1994-08-31
  7 in total
  1 in total

1.  Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer.

Authors:  M Martín-Jiménez; A Rodríguez-Lescure; M Ruiz-Borrego; M-A Seguí-Palmer; M Brosa-Riestra
Journal:  Clin Transl Oncol       Date:  2009-01       Impact factor: 3.405
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.